Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity

Bone Marrow Transplantation

Volumn 18, Issue 4, 1996, Pages 713-720

  Condiotti, R ^a   Nagler, A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

AlloPBSCT; Campath 1; Conjugation; Cytotoxicity; Natural killer cells; Proliferation

Indexed keywords

ALEMTUZUMAB; CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 2;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; CANCER REGRESSION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LARGE GRANULAR LYMPHOCYTE; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, CD56; BONE MARROW TRANSPLANTATION; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; RATS; RECEPTORS, IGG; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029824828     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hale G, Xia MQ, Tighe HP et al. The Campath-1 antigen (CDw52). Tiss Antigen 1990; 35: 118-127.
2. Waldmann H. Manipulation of T-cell responses with monoclonal antibodies. Ann Rev Immunol 1989; 7: 407-444.
3. Xia MQ, Tone M, Packman L et al. Characterization of the Campath-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991; 21: 1677-1684.
4. Waldmann H, Hale G, Cividalli G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 1984; 2: 483-486.
5. Slavin S, Waldmann H, Or R et al. Prevention of graft-versus-host disease in allogeneic bone marrow transplantation for leukemia by T cell depletion in vitro prior to transplantation. Transplant Proc 1985; 17: 465-467.
6. Slavin S, Or R, Naparstak E et al. New approaches for prevention of rejection and graft-versus-host disease in clinical bone marrow transplantation. Israel J Med Sci 1986; 22: 264-267.
7. Kirschbaum M, Nagler A, Naparstek E et al. Use of G-CSF mobilized T-cell depleted peripheral blood and bone marrow stem cells for allogeneic BMT. Blood 1995; 86: 580a.
8. Naparstek E, Or R, Nagler A et al. T cell depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-515.
9. Hale G, Waldmann H. Recent results using Campath-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant 1996; 17: 305-308.
10. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
11. Porter DL, Rothe MS, McGarible C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
12. Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
13. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
14. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 6: 2195-2204.
15. MacKinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
16. Jiang YZ, Cullis JO, Kanfer EJ et al. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1993; 11: 133-138.
17. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft-vs-leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Immunol Immunother 1990; 31: 236-242.
18. Slavin S, Ackerstein A, Naparstek E et al. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant 1990; 6: 155-161.
19. + T cell activity. J Immunol 1993; 150: 197-205.
20. Mehta J. Graft-versus-leukemia reaction in clinical bone marrow transplantation. Leuk Lymphoma 1993; 10: 421-432.
21. Dreger P, Suttorp M, Haferlach T et al. Allogeneic G-CSF-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplanation. Blood 1993; 81: 1404-1407.
22. Weaver CH, Bensinger W, Longin K et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981-1984.
23. Russell NH, Hunter A, Rogers S et al. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 241: 1482.
24. Parrado A, Casares S, Carmona M et al. Natural killer (NK) cell recovery following autologous peripheral blood stem cell transplantation is significantly faster than that following autologous or allogeneic bone marrow transplantation: use of G-CSF contributes to accelerate NK cell recovery. Bone Marrow Transplant 1996 (in press).
25. + selection systems or Campath-1. Exp Hematol 1995; 23: 147-154.
26. Morecki S, Nabet C, Ackerstein A et al. The effect of in vitro T lymphocyte depletion on generation of IL-2-activated cytotoxic cells. Bone Marrow Transplant 1991; 7: 269-273.
27. Fabian I, Flidel O, Gadish M et al. Effects of Campath-1 antibodies on monocytes and polymorphonuclear neutrophils. Exp Hematol 1993; 21: 1522-1527.
28. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814-825.
29. Deutsch VR, Nagler A, Slavin S et al. Effect of bone marrow T lymphocytes treated with Campath-1G on megakaryocyte colony formation. Exp Hematol 1993; 21: 1427-1435.
30. Nagler A, Lanier LL, Phillips JH. The effects of IL-4 on human natural killer cells: a potent regulator of IL-2 activation and proliferation. J Immunol 1988; 141: 2349-2351.
31. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcR III-positive and negative natural killer cells. J Immunol 1989; 143: 3183-3191.
32. Lebow LT, Bonavida B. Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets. Proc Natl Acad Sci USA 1990; 87: 6063-6067.
33. Purussia B, Starr S, Abraham S et al. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol 1983; 130: 2133-2141.
34. Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 1988; 141: 3478-3485.
35. Lovchik JC, Hong R. Antibody-dependent cell-mediated cytolysis (ADCC): analyses and projections. Prog Allergy 1977; 22: 1-44.
36. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 1982; 79: 4761-4765.
37. Rowan WC, Hale G, Tit JP, Brett SJ. Cross-linking of the Campath-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1994; 7: 69-77.
38. Valentin H, Gelin C, Coulombel L et al. The distribution of the CDw52 molecule on blood cells and characterization of its involvement in T cell activation. Transplantation 1992; 54: 97-104.
39. Nagler A, Rabinowitz R, Rosengolts J et al. The development and relationship between natural killer (NK) and T cells post-bone marrow transplantation (BMT). Exp Hematol 1995; 23: 856a.